^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association of increased somatic mutations in metastatic melanoma patients with clinical outcome.
Published date:
05/16/2018
Excerpt:
...108 metastatic melanoma patients enrolled...All patients received immunotherapy first line treatment...Worse PFS was observed with EGFR (HR = 8.22, p = 0.04), PTEN (HR = 1.92, p = 0.04) and non-canonical BRAF (HR = 1.77, p = 0.04) mutations....those that harbored a higher number of mutations were associated with a worse PFS...
DOI:
10.1200/JCO.2018.36.15_suppl.e21568
